SkinHealth Systems Reports Q3 2026 Results with Increased EBITDA Guidance Amidst Declining Equipment Sales
SkinHealth Systems (SKIN) reported third-quarter revenue of $69.2 million, a slight year-over-year decrease of 2.1% driven by lower delivery system unit placements. Despite the decline in equipment sales due to capital expenditure constraints among providers, the company saw strong performance in its consumables segment, which grew to $50.4 million. This growth was bolstered by the HydraScalp relaunch and a 39% surge in SkinStylus consumables. The company demonstrated significant operational efficiency, reporting an Adjusted EBITDA of $13.4 million—a 50% increase year-over-year—and returning to a GAAP operating income of $5 million. While EMEA and APAC markets faced headwinds due to execution challenges and distributor transitions, the Americas region remained stable. Based on these results, SkinHealth Systems raised its full-year Adjusted EBITDA guidance to a range of $48 million to $50 million.
Topics: adjusted EBITDA consumables revenue delivery systems gross margin net sales revenue